🟢 Tenax Therapeutics is trading 10.6% up today after positive Phase 3 melanoma vaccine results

Tenax Therapeutics is trading 10.6% up at $1.88 as biotechnology sentiment improves following positive Phase 3 melanoma vaccine results from Moderna and Merck.

• Reuters reported that the treatment met its primary and secondary goals, supporting the broader sector move.
• No new company-specific announcement was found for August 19, 2026.
• The rebound follows the earlier Phase 3 LEVEL trial failure, which Reuters reported sent shares sharply lower on August 10.